Gypenoside LI

Research use only, not for human use.

Gypenoside LI possesses non-small cell lung carcinoma A549 cell inhibitory activity.

Gypenoside LI possesses non-small cell lung carcinoma A549 cell inhibitory activity.

Gypenoside LI (0-80 μM) inhibits A549 cells in a dose-dependent manner. Gypenoside LI induces G2/M and arrest apoptosis in A549 cells.Gypenoside LI increases intracellular ROS level. Gypenoside LI suppressed migration of A549 cells.Gypenoside LI could obviously suppress the expression of CDK1 protein rather than CDK2 and CDK4 proteins.Gypenoside LI inhibits cell proliferation and upregulates expression of miR-128-3p in melanoma cells.Gypenoside LI (75 and 29.71 μg/mL) can induce intrinsic apoptosis along with S phase arrest. Gypenoside LI inhibited the colony formation ability of melanoma through inhibition of the Wnt/β-catenin signaling pathway.Gypenoside LI induces PARP cleavage, increased the expression of cleaved caspase-9 and BID death agonist, and downregulates the expression of FLIP (long form) and BCl-2 in the A375 and SK-MEL-28 melanoma cells. Cell Viability Assay Cell Line:A549 cells.Concentration:0-80 μM.Incubation Time:24 h.Result:Displayed the strongest activity with the IC50 values of 21.36 ± 0.78 μM.

——

——

Others

Other Targets

——

——

——

94987-10-7

801

C42H72O14

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (124.84 mM)

——

——

(-20℃)

With Ice Pack

≥ 2 years